Emergent BioSolutions
eröffnet am 29.10.08 02:00:45 von
neuester Beitrag 08.11.23 23:17:01 von
neuester Beitrag 08.11.23 23:17:01 von
Beiträge: 15
ID: 1.145.645
ID: 1.145.645
Aufrufe heute: 0
Gesamt: 3.600
Gesamt: 3.600
Aktive User: 0
ISIN: US29089Q1058 · WKN: A0LC2W · Symbol: ER4
4,1090
EUR
+0,10 %
+0,0040 EUR
Letzter Kurs 08.05.24 Tradegate
Neuigkeiten
02.05.24 · wO Chartvergleich |
01.05.24 · globenewswire  |
01.05.24 · globenewswire |
01.05.24 · globenewswire |
30.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 2,1000 | +33,76 | |
| 4,0600 | +27,67 | |
| 1,6400 | +25,19 | |
| 26,45 | +23,02 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,5000 | -28,30 | |
| 0,6864 | -32,57 | |
| 2,1300 | -34,41 | |
| 2,4780 | -35,84 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Q3: https://investors.emergentbiosolutions.com/
• Third Quarter 2023 Total Revenues of $271M, above the prior guidance range
• Third Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20M
• Updates FY 2023 guidance
...
10-Q dauert noch:
As part of our quarterly review process, the Company determined that its state deferred tax liability was overstated as of December 31, 2022, resulting in an understatement of the income tax benefits reflected on the Company’s income statement. While these non-cash items do not have any impact on the Company’s liquidity, cash flow, historical management compensation or covenant compliance, we have concluded that it is appropriate to delay the disclosure of full third quarter and year-to-date earnings information and the filing of our Quarterly Report on Form 10-Q for the period ended September 30, 2023 while we work to correct our prior period financial statements. We expect to complete this work in the near future.
...
...
• Third Quarter 2023 Total Revenues of $271M, above the prior guidance range
• Third Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20M
• Updates FY 2023 guidance
...
10-Q dauert noch:
As part of our quarterly review process, the Company determined that its state deferred tax liability was overstated as of December 31, 2022, resulting in an understatement of the income tax benefits reflected on the Company’s income statement. While these non-cash items do not have any impact on the Company’s liquidity, cash flow, historical management compensation or covenant compliance, we have concluded that it is appropriate to delay the disclosure of full third quarter and year-to-date earnings information and the filing of our Quarterly Report on Form 10-Q for the period ended September 30, 2023 while we work to correct our prior period financial statements. We expect to complete this work in the near future.
...
...
https://www.emergentbiosolutions.com/media-statement/a-state…
A Statement on Emergent’s Camden Manufacturing Facility Regulatory Status
GAITHERSBURG, Md., October 5, 2023 – Emergent (NYSE: EBS) received important communications from the U.S. Food and Drug Administration (FDA) regarding its Camden drug product manufacturing facility in Baltimore, Maryland.
This week, FDA sent Emergent a “Warning Letter close-out letter,” regarding its Camden facility, stating that “it appears that [Emergent has] adequately addressed the violations contained in the Warning Letter” originally issued in August 2022. FDA has also communicated to Emergent that the inspection classification for its Camden facility is “Voluntary Action Indicated” and that the inspection is considered “closed.” This is regarding an FDA inspection from February 2022, which classified the Camden facility as “Official Action Indicated.”
Emergent is committed to ensuring continued compliance with Current Good Manufacturing Practice requirements and remains steadfast in manufacturing and delivering high-quality products across its global network of manufacturing facilities.
...
A Statement on Emergent’s Camden Manufacturing Facility Regulatory Status
GAITHERSBURG, Md., October 5, 2023 – Emergent (NYSE: EBS) received important communications from the U.S. Food and Drug Administration (FDA) regarding its Camden drug product manufacturing facility in Baltimore, Maryland.
This week, FDA sent Emergent a “Warning Letter close-out letter,” regarding its Camden facility, stating that “it appears that [Emergent has] adequately addressed the violations contained in the Warning Letter” originally issued in August 2022. FDA has also communicated to Emergent that the inspection classification for its Camden facility is “Voluntary Action Indicated” and that the inspection is considered “closed.” This is regarding an FDA inspection from February 2022, which classified the Camden facility as “Official Action Indicated.”
Emergent is committed to ensuring continued compliance with Current Good Manufacturing Practice requirements and remains steadfast in manufacturing and delivering high-quality products across its global network of manufacturing facilities.
...
Verfolgt die noch jemand? Wieso so viel runter?
wegen:
10.4.
Emergent Biosolutions Upgraded After FDA Approves Narcan OTC Sales
https://www.marketwatch.com/articles/emergent-biosolutions-u…
29.3.
FDA Makes Overdose-Reversal Drug Narcan Available Over-the-Counter
Emergent BioSolutions is first company to gain approval to sell naloxone without a prescription
https://www.wsj.com/articles/fda-approves-narcan-for-non-pre…
...
People will soon be able to walk into a pharmacy and purchase medication to reverse an opioid overdose alongside other nonprescription items like aspirin and vitamins.
The Food and Drug Administration on Wednesday said the overdose reversal medication Narcan could be sold over-the-counter for the first time since the opioid crisis began. Narcan’s manufacturer, Emergent BioSolutions Inc., said the nasal-spray version of the medication naloxone would likely begin appearing on shelves by late summer. Emergent is the first company to gain approval to sell naloxone without a prescription.
...
<Erst-Spass-Posi>
FDA Makes Overdose-Reversal Drug Narcan Available Over-the-Counter
Emergent BioSolutions is first company to gain approval to sell naloxone without a prescription
https://www.wsj.com/articles/fda-approves-narcan-for-non-pre…
...
People will soon be able to walk into a pharmacy and purchase medication to reverse an opioid overdose alongside other nonprescription items like aspirin and vitamins.
The Food and Drug Administration on Wednesday said the overdose reversal medication Narcan could be sold over-the-counter for the first time since the opioid crisis began. Narcan’s manufacturer, Emergent BioSolutions Inc., said the nasal-spray version of the medication naloxone would likely begin appearing on shelves by late summer. Emergent is the first company to gain approval to sell naloxone without a prescription.
...
<Erst-Spass-Posi>
Trading Spotlight
Antwort auf Beitrag Nr.: 72.171.198 von Plomo_o_plata am 11.08.22 03:18:15https://www.finanzen.at/nachrichten/aktien/cepi-vergibt-vert…
Neuer virus aus cn
https://www.welt.de/vermischtes/weltgeschehen/article2403971…Bin der Meinung ebs forscht hier seit 2018
Seltsam. Warum nimmt das kaum einer zur Kenntnis?
Besser gehts doch gar nicht...vom RKI, Seite 6:
https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungna…
Da heißt es:
"Bei Kontraindikationen für Tecovirimat sowie fulminantem Verlauf kann zudem die
Anwendung humaner Vaccinia-Immunglobuline erwogen werden. Vaccinia
Immunglobulin (VIGIV, Emergent Biosolution) ist zur Behandlung von Komplikationen
der klassischen Pockenimpfung zugelassen. Daten zur Behandlung oder Prophylaxe
von Affenpocken liegen nicht vor. Dennoch empfiehlt die CDC, dass bei Patienten mit
schweren T-Zell-Defekten, bei denen eine Impfung kontraindiziert ist, eine Behandlung
und auch eine prophylaktische Gabe mit dem Vaccinia Immunglobulin erwogen wird."
(https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.…
Besser gehts doch gar nicht...vom RKI, Seite 6:
https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungna…
Da heißt es:
"Bei Kontraindikationen für Tecovirimat sowie fulminantem Verlauf kann zudem die
Anwendung humaner Vaccinia-Immunglobuline erwogen werden. Vaccinia
Immunglobulin (VIGIV, Emergent Biosolution) ist zur Behandlung von Komplikationen
der klassischen Pockenimpfung zugelassen. Daten zur Behandlung oder Prophylaxe
von Affenpocken liegen nicht vor. Dennoch empfiehlt die CDC, dass bei Patienten mit
schweren T-Zell-Defekten, bei denen eine Impfung kontraindiziert ist, eine Behandlung
und auch eine prophylaktische Gabe mit dem Vaccinia Immunglobulin erwogen wird."
(https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.…
Dito 👍 gutes Gelingen
Durch die Affenpocken spannender als je zurvor..!
Bin mit nem kleinen Wert rein... denke aber da kommt noch ein guter Anstieg auf uns zu..!
Bin mit nem kleinen Wert rein... denke aber da kommt noch ein guter Anstieg auf uns zu..!
Durchsuchen
Emergent BioSolutions
